The cases of peripheral nerve injury (PNI) are rising, and the slow regeneration process in PNI patients leads to loss of nerve functions. In addition, research on the mechanism of peripheral nerve regeneration has accelerated significantly, and researchers are seeking different methods to enhance peripheral nerve regeneration. Platelets-rich protein (PRP) therapy integrates mainstream technologies for repairing and rejuvenating the tissues damaged due to injury or chronic diseases. PRP injections have improved regenerative medicine treatments for wound healing, skin regeneration, cosmetic and plastic surgery, and orthopedic procedures in the past few years.
Evidence has shown that micro-needling (MN) and topical application, along with PRP, improve collagen production and skin tightening for vampire facials. According to the report "Combined micro needling with topical application of platelet-rich plasma versus micro-needling alone in the treatment of stria distensae" published in 2020, MN-PRP was associated with an excellent improvement of skin lesions of Striae distensae (SD), more significant deposition of collagen and elastic fibers, increased proliferative activity in epidermis, and decreased caspase-3 protein expression values in epidermis. It has also been used to treat skin pigmentation disorders and acne scars. In hair transplants, PRP can bind to growth factors and elevates the proliferation of human derma papilla cells leading to the formation and maintenance of hair follicles. PRP injections are gaining popularity for treating various conditions, from sports injuries to hair loss. PRP can be widely used in regenerative medicines owing to its tissue regeneration capability, which is likely to provide lucrative opportunities for the blood plasma derivatives market in the coming years.
Asia Pacific blood plasma derivatives market has been segmented into the China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China is expected to account for the largest market share and is expected to develop moderately in the Asia Pacific.
The factors evaluated to impact the growth of the market are the increasing number of organizations that ensure the supply of blood plasma, along with the presence of countries that are major contributors in terms of market growth aspects of the region. In China, there is wide use of blood plasma for various treatments, and the country is making huge contributions to the blood plasma market in the Asia Pacific region. China also accounted for many fractionation facilities, the highest in the Asia Pacific region. The country encompasses lucrative opportunities in terms of novel plasma therapy production. The hospital industry of the country is recording rapid growth due to advanced healthcare reforms. According to an article, the country is one of the largest manufacturers or consumers in the plasma-derived product market.
The Asia Pacific blood plasma derivatives market is segmented into type, application, end user, and country.
The Asia Pacific blood plasma derivatives market, by type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held a larger market share in 2022.
Based on application, the Asia Pacific blood plasma derivatives market is divided into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The immunodeficiency diseases applications segment held the largest share of the market in 2022.
The blood plasma derivatives market, by end user, is segmented into hospitals, diagnostic laboratories, clinics, and other end users. The hospitals segment held the largest share of the market in 2022.
Based on country, the Asia Pacific blood plasma derivatives market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.
Grifols SA; SK Plasma Co Ltd; Octapharma AG; Monobind Inc.; Intas Pharmaceuticals Ltd; Takeda Pharmaceutical Co Ltd; CSL Behring LLC; LFB SA; Kedrion SpA; and Fusion Health Care Pvt Ltd are the leading companies operating in the Asia Pacific blood plasma derivatives market.